{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:08:42Z","timestamp":1779361722843,"version":"3.51.4"},"reference-count":36,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Risk &amp; Safety in Medicine"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To analyse regulatory positions and drug policies of the Commonwealth of Independent States (CIS), compared to those of the EU, UK, USA i of the nootropics, used in Russia for Alzheimer\u2019s disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched E-library to reveal the list of nootropics used and studied in Russia for Alzheimer\u2019s disease. We assessed official pharmaceutical registries of nine countries for registration status of identified nootropics, 7 National Essential Medicines Lists (EML), and four clinical practice guidelines (CPG) on Alzheimer\u2019s disease. We compared the results of Russia with other countries regulatory and policy positions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>E-Library searches identified 11 nootropicspiracetam, citicoline, idebenone, vinpocetine, choline alfoscerate, Cerebrolysin\u00ae, Kortexin\u00ae, ethylmethylhydroxypyridine succinate, glycine, nicergoline, nimodipine. Eight nootropic have registration for use in all CIS countries (excluding idebenone, nimodipine), four (piracetam, nimodipine, nicergoline, idebenone) \u2013 in UK, nimodipine \u2013 in the USA, and idebenone \u2013 in EU. National EMLs included: nine nootropics (Russia), 8 \u2013 Belarus and Kazakhstan, 4 \u2013 Uzbekistan, 2 \u2013 Armenia. The studied nootropic agents are not included on the WHO Model EML and on the National EML of the Kyrgyz Republic. They are not listed in the CPG for Treatment of dementia and Alzheimer\u2019s disease in the USA, the EU, and the UK. Russian CPGs for Alzheimer\u2019s disease recommend Cerebrolysin\u00ae and choline alfoscerate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The studied nootropics are registered for use and listed on National EMLs of Russia, Armenia, Belarus, Kazakhstan, Uzbekistan. None is included on the WHO Model EML and the National EML of Kyrgyzstan, Only CPG of the RF recommend using two nootropics as adjuvant therapy of Alzheimer\u2019s disease, Cerebrolysin\u00ae and choline alfoscerate. CPG of the European Union, the United Kingdom, and the USA do not mention nootropics as potential treatment options for Alzheimer\u2019s disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09246479251410817","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T10:13:22Z","timestamp":1767089602000},"page":"257-264","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of nootropics in Alzheimer\u2019s disease: An analysis of regulatory positions and drug policies in the countries of the Commonwealth of Independent States"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8206-9866","authenticated-orcid":false,"given":"Elvira Grigorievna","family":"Alexandrova","sequence":"first","affiliation":[{"name":"Kazan (Volga Region) Federal University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6321-5859","authenticated-orcid":false,"given":"Tatyana Rudolfovna","family":"Abakumova","sequence":"additional","affiliation":[{"name":"Kazan (Volga Region) Federal University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1999-0705","authenticated-orcid":false,"given":"Liliya Eugenevna","family":"Ziganshina","sequence":"additional","affiliation":[{"name":"RUDN University"},{"name":"Kazan State Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2013.12.024"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-821556-2.00028-1"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0364-7722(77)90046-7"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(94)00398-X"},{"key":"e_1_3_3_6_2","first-page":"824","volume-title":"Textbook of psychopharmacology","author":"Schatzberg AF","year":"2007","unstructured":"Schatzberg AF, Nemeroff CB. Textbook of psychopharmacology. American Psychiatric Association, 2007, p. 824."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.12688\/healthopenres.13504.1"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0278-5846(89)90112-7"},{"issue":"2","key":"e_1_3_3_9_2","first-page":"121","article-title":"Cognitive impairment and nootropic drugs: mechanism of action and spectrum of effects","volume":"40","author":"Voronina TA","year":"2022","unstructured":"Voronina TA. Cognitive impairment and nootropic drugs: mechanism of action and spectrum of effects. Neurochemistry 2022; 40(2): 121\u2013131, (In Russ.).","journal-title":"Neurochemistry"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11164661"},{"key":"e_1_3_3_11_2","unstructured":"State Register of Medicines. State Register of Medicines of the Russian Federation [Internet]. [cited 2005 May 10]. Available from: https:\/\/grls.minzdrav.gov.ru\/Default.aspx"},{"key":"e_1_3_3_12_2","unstructured":"National Center for Expertise of Medicines and Medical Devices State Register of Medicines and Medical Devices of the Republic of Kazakhstan [cited 2005 May 10]. Available from: http:\/\/register.ndda.kz\/category\/search_prep"},{"key":"e_1_3_3_13_2","unstructured":"Registers of the State Enterprise \u201cCenter for Expertise and Testing in Healthcare\u201d. State Register of Medicines of the Republic of Belarus [cited 2005 May 10]. Available from: https:\/\/www.rceth.by\/Refbank"},{"key":"e_1_3_3_14_2","unstructured":"Department of Medicines and Medical Devices under the Ministry of Health of the Kyrgyz Republic. State Register of Medicines and Medical Devices of the Kyrgyz Republic [cited 2005 May 10]. Available from: https:\/\/ndb.med.kg\/pages\/registry"},{"key":"e_1_3_3_15_2","unstructured":"Center for Expertise in Medicines and Medical Technologies (SNCO). Register of Registered Medicines of the Republic of Armenia [cited 2005 May 10]. Available from: http:\/\/pharm.cals.am\/pharm\/drug_images\/index.php"},{"key":"e_1_3_3_16_2","unstructured":"Ministry of Health of the Republic of Uzbekistan. State Register of Medicines and Medical Devices of the Republic of Uzbekistan [cited 2005 May 10]. Available from: https:\/\/uzpharm-control.uz\/ru\/pages\/state-register-of-medicines-and-medical-products"},{"key":"e_1_3_3_17_2","unstructured":"U.S. Food and Drug Administration (FDA) [cited 2005 May 10]. Available from: https:\/\/www.fda.gov\/drugs"},{"key":"e_1_3_3_18_2","unstructured":"The Medicines and Healthcare products Regulatory Agency UK [cited 2005 May 10]. Available from: https:\/\/products.mhra.gov.uk\/"},{"key":"e_1_3_3_19_2","unstructured":"The European Medicines Agency (EMA) of the European Union [cited 2005 May 10]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines"},{"key":"e_1_3_3_20_2","unstructured":"\u0421ollection of databases in medicine and other healthcare specialties Cochrane Library [cited 2025 Sept 10]. Available from: https:\/\/www.cochranelibrary.com\/"},{"key":"e_1_3_3_21_2","unstructured":"List of vital and essential drugs for medical use in the Russian Federation. https:\/\/www.consultant.ru\/document\/cons_doc_LAW_335635\/ (2025 accessed 10 May 2025)."},{"key":"e_1_3_3_22_2","unstructured":"National list of essential medicines of the Kyrgyz Republic. https:\/\/cbd.minjust.gov.kg\/11924\/edition\/17581\/ru (2024 accessed 10 May 2025)."},{"key":"e_1_3_3_23_2","unstructured":"List of essential medicines of the Republic of Belarus. https:\/\/minzdrav.gov.by\/upload\/lcfiles\/\u043f\u043e\u0441\u0442\u0430\u043d\u043e\u0432\u043b\u0435\u043d\u0438\u0435_\u041c\u0417_2007_65.pdf (2024 accessed 10 May 2025)."},{"key":"e_1_3_3_24_2","unstructured":"List of strategically important medicines and medical products of the Republic of Kazakhstan. https:\/\/adilet.zan.kz\/rus\/docs\/V2300032025 (2023 accessed 10 May 2025)."},{"key":"e_1_3_3_25_2","unstructured":"List of essential medicines of the Republic of Armenia. https:\/\/www.arlis.am\/hy\/acts\/179164 (2025 accessed 30 May 2025)."},{"key":"e_1_3_3_26_2","unstructured":"List of essential medicines of the Republic of Uzbekistan. https:\/\/www.norma.uz\/novoe_v_zakonodatelstve\/obnovlen_perechen_osnovnyh_lekarstvennyh_sredstv (2023 accessed 10 May 2025)."},{"key":"e_1_3_3_27_2","unstructured":"WHO model list of essential medicines - 24rd list. https:\/\/www.who.int\/publications\/i\/item\/B09474 (2025 accessed 05 September 2025)."},{"key":"e_1_3_3_28_2","unstructured":"Clinical guidelines \u201cCognitive disorders in elderly and senile persons\u201d. https:\/\/cr.minzdrav.gov.ru\/view-cr\/617_5 (2024 accessed 10 May 2025)."},{"key":"e_1_3_3_29_2","unstructured":"Dementia: assessment management and support for people living with dementia and their carers. https:\/\/www.nice.org.uk\/guidance\/ng97 (2018 accessed 10 May 2025)."},{"key":"e_1_3_3_30_2","unstructured":"Dementia. https:\/\/www.ninds.nih.gov\/health-information\/disorders\/dementias (2024 accessed 10 May 2025)."},{"key":"e_1_3_3_31_2","unstructured":"Guideline on the clinical investigation of medicines for the treatment of Alzheimer\u2019s disease. https:\/\/www.tga.gov.au\/resources\/resource\/international-scientific-guidelines\/guideline-clinical-investigation-medicines-treatment-alzheimers-disease (2024 accessed 10 May 2025)."},{"key":"e_1_3_3_32_2","doi-asserted-by":"crossref","unstructured":"Cui S Chen N Yang M et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev 2019(11): CD008900.","DOI":"10.1002\/14651858.CD008900.pub3"},{"key":"e_1_3_3_33_2","doi-asserted-by":"crossref","unstructured":"Szatm\u00e1ri S Whitehouse P. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev. 2003(1): CD003119.","DOI":"10.1002\/14651858.CD003119"},{"key":"e_1_3_3_34_2","unstructured":"Flicker L Grimley Evans J. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev 2001(2): CD001011."},{"key":"e_1_3_3_35_2","doi-asserted-by":"crossref","unstructured":"Fioravanti M Yanagi M. Cytidinediphosphocholine (CDP\u2010choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev 2005(2): CD000269.","DOI":"10.1002\/14651858.CD000269.pub2"},{"key":"e_1_3_3_36_2","unstructured":"L\u00f3pez\u2010Arrieta J Birks J. Nimodipine for primary degenerative mixed and vascular dementia. Cochrane Database Syst Rev 2002(3): CD000147."},{"key":"e_1_3_3_37_2","doi-asserted-by":"crossref","unstructured":"Fioravanti M Flicker L. Nicergoline for dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev 2001(4): CD003159.","DOI":"10.1002\/14651858.CD003159"}],"container-title":["International Journal of Risk &amp; Safety in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09246479251410817","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09246479251410817","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09246479251410817","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:58:49Z","timestamp":1779361129000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09246479251410817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1177\/09246479251410817"],"URL":"https:\/\/doi.org\/10.1177\/09246479251410817","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/09246479251410817\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479251410817\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479251410817\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479251410817\/v1\/review1","asserted-by":"object"}]},"ISSN":["0924-6479","1878-6847"],"issn-type":[{"value":"0924-6479","type":"print"},{"value":"1878-6847","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]}}}